Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise

Immune checkpoint inhibitors are monoclonal antibodies that are used to treat over one in three cancer patients. While they have changed the natural history of disease, prolonging life and preserving quality of life, they are highly active in less than 40% of patients, even in the most responsive ma...

Full description

Bibliographic Details

Published in:	Diagnostics
Main Authors:	Brian Healey Bird, Ken Nally, Karine Ronan, Gerard Clarke, Sylvie Amu, Ana S. Almeida, Richard Flavin, Stephen Finn
Format:	Article
Language:	English
Published:	MDPI AG 2022-01-01
Subjects:	cancer immunotherapy biomarker microenvironment microbiome flow cytometry
Online Access:	https://www.mdpi.com/2075-4418/12/1/124